Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
92.03%
Net Margin
112.18%
Efficiency Metrics
Revenue per Expense Ratio
12.55
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
1.8000000000
Balance Sheet Analysis
Current Ratio
0.59
Cash Ratio
0.04
Working Capital
$-16.04M
Debt to Equity
0.55
Debt to Assets
33.72%
Equity Ratio
61.50%
Cash Flow Analysis
Operating Cash Flow Ratio
67.55%
Free Cash Flow Ratio
67.55%
CapEx to Revenue
0.00%
Dividends Paid
$43.09M
Stock Buybacks
No buybacks
Total Shareholder Returns
$43.09M
Cash Position Change
-46.90%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 2.50%
Detailed Growth Metrics
Core Performance
Revenue
187.40%
Net Income
151.02%
EPS
150.99%
Operating Income
11,324.15%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
1,032.62%
Operating Cash Flow
-47.97%
Free Cash Flow
-47.97%
Balance Sheet Health
Assets
2.63%
Debt
0.07%
Book Value per Share
4.39%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
2.50%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
50.86%
5Y Revenue/Share
52.72%
3Y Dividend/Share
2.26%
5Y Dividend/Share
283.34%